Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Nanobiotix Presents Successful Phase I Results for NBTXR3 at ASCO

Published: Tuesday, June 03, 2014
Last Updated: Tuesday, June 03, 2014
Bookmark and Share
Final results demonstrate a very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas.

NANOBIOTIX has announced the successful completion of the first in human study of its lead NanoXray product, NBTXR3, which will be presented at the American Society of Clinical Oncology (ASCO) annual meeting.

The Phase I clinical study established that intratumoral injection of NBTXR3 followed by radiotherapy has a good safety profile in patients with locally advanced soft tissue sarcoma (STS), who have an important risk of relapse and few treatment options.

These results allow Nanobiotix to proceed to the pivotal phase, which is the final step leading to registration (CE mark).

The study showed that promising signs of antitumor activity for different sarcoma subtypes were observed. Interestingly, tumor shrinkage and pathological response were observed in well-known refractory tumors. All patients underwent a wide surgical resection. This optimal surgery impacts the local recurrence rate, improving patient prognosis since local disease control prolongs progression free survival and overall survival in high grade sarcomas.

Elsa Borghi, CMO of Nanobiotix said: “These results are really encouraging, the feasibility of injecting different sarcoma subtypes with varying volumes of NBTXR3 nanoparticles was tested in this phase I study and a very good tolerance was observed. We are pleased to announce that each patient has been successfully operated on. This has reinforced the fact that radiotherapy with NBTXR3 has the potential to be an effective pre-operative treatment and offer meaningful clinical benefit to patients with advanced Soft Tissue Sarcoma (STS). Now, further development of NBTXR3 is warranted and a pivotal trial is planned to start in Q4 2014.”

The study enrolled 20 patients who received a single intratumoral injection of NBTXR3, at escalating volumes, followed by standard radiotherapy (50Gy RTx), as indicated in this clinical setting.

Primary endpoints included feasibility of the intratumoral implantation and safety. Secondary endpoints focused on the efficacy such as pathological response and RECIST (Response Evaluation Criteria In Solid Tumors) response, including tumor volume evaluation. Moreover, IntraTumoral permanence of NBTXR3 and operability were assessed.

Key findings:

Feasibility of the NBTXR3 injection within the tumor mass across different tumor types and volumes (from 55.06ml to 3682.56ml) was demonstrated.
No leakage of NBTXR3 to the surrounding healthy tissues was confirmed.
• Persistence of NBTXR3 during all sessions of radiotherapy: optimal bioavailability over time.
• Appropriate dispersion of the product within the tumor: diffusion in 3 dimensions.
Very good tolerance and local safety of the product at volume 2.5%, 5%, 10% and 20% was observed.
Promising signs of antitumor activity were observed in different sarcoma subtypes, such as undifferentiated sarcoma, rhabdomyosarcoma, and synovial sarcoma.
The recommended volume for the pivotal study is 10%.

Laurent Levy, CEO of Nanobiotix commented: “The completion of this Phase I study is a very important milestone for Nanobiotix. The next step for us is to initiate a pivotal study for NBTXR3 in patients with advanced soft tissue sarcomas. We expect to start enrolling patients by the end of 2014. This successful feasibility of our NBTXR3 approach in cancer patients also encourages us to expand the use of NBTXR3 in other indications like head and neck cancer, liver cancer, glioblastoma, rectal cancer and prostate cancer, and to think about developments of our other products, NBTX-IV and NBTX-TOPO.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Nanobiotix Half Year Results for the Six Months Ended 30 June 2014
Significant operational and clinical progress made.
Tuesday, September 02, 2014
Nanobiotix Sees Clinical Advance in STS Pilot Trial with Lead Product, NBTXR3
Market development plan outlined for earlier potential launch in 2016.
Tuesday, February 11, 2014
NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
NANOBIOTIX announced it has been awarded the “Young Talent” Award at the INVESTOR AWARDS 2013, referring to a newly listed company.
Friday, November 08, 2013
Nanobiotix Announces €2.8 Million Grant to Develop NBTXR3
Through ETPN, Nanobiotix is driving nanomedicine in Europe and is now involved in the first nanomedicine consortium in France with the launch of NICE project.
Friday, July 05, 2013
Nanobiotix Receives Approval from ANSM to Start New Clinical Trial with NBTXR3
Second indication for NanoXray product in Head and Neck cancer patients.
Thursday, June 13, 2013
Scientific News
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.
Milestone Single-Biomolecule Imaging Technique May Advance Drug Design
The first nanometer resolved image of individual tobacco mosaic virions shows the potential of low-energy electron holography for imaging biomolecules at a single particle level; a milestone in structural biology and a potential new tool for drug design.
Opening the Door to Safer, More Precise Cancer Therapies
New method regulates when, and how strongly, cancer-killing therapeutic T cells are activated.
Biologists Find Unexpected Role for Amyloid-Forming Protein
Yeast protein could offer clues to how Alzheimer’s plaques form in the brain.
Revolutionary Gene-editing Technique to Stop AIDS Virus in Its Tracks
UNLV personalized medicine researchers seeking patent on potential HIV cure. Their technique uses a plant protein widely used in agriculture industry.
Viruses Join Fight Against Harmful Bacteria
Engineered viruses could combat human disease and improve food safety.
Tracking Changes in DNA Methylation In Real Time At Single-Cell Resolution
Whitehead Institute researchers have developed a methodology to monitor changes in DNA methylation over time in individual cells.
Virus Re-Engineered to Deliver Targeted Therapies
Researchers stripped a virus of its infectious machinery and turned its benign core into a delivery vehicle that can target sick cells while leaving healthy tissue alone.
Exposure to Pesticides In Childhood Linked to Cancer
Young children who are exposed to insecticides inside their homes may be slightly more at risk for developing leukemia or lymphoma during childhood, according to a meta-analysis by Harvard T.H. Chan School of Public Health researchers.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos